Study identifier:NIS-CME-XXX-2012/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)
Diabetes Mellitus, Non-Insulin-Dependent
N/A
No
-
All
733
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2014 by AstraZeneca
AstraZeneca
-
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent. In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.
Location
Location
Bucuresti, Romania
Location
Alexandria, Romania
Location
Brasov, Romania
Location
Cluj, Romania
Location
Constanta, Romania
Location
Craiova, Romania
Location
Tg Jiu, Romania
Location
Galati, Romania
Arms | Assigned Interventions |
---|---|
Patients with diabetes type 2 | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.